EP Patent

EP3160461A1 — Transdermal delivery system

Assigned to KAT Transdermals LLC · Expires 2017-05-03 · 9y expired

What this patent protects

Embodiments of the invention relate generally to the field of transdermal delivery and more specifically to transdermal patches containing rasagiline for the treatment of depression, Parkinson's disease, and other nervous system conditions.

USPTO Abstract

Embodiments of the invention relate generally to the field of transdermal delivery and more specifically to transdermal patches containing rasagiline for the treatment of depression, Parkinson's disease, and other nervous system conditions.

Drugs covered by this patent

Patent Metadata

Patent number
EP3160461A1
Jurisdiction
EP
Classification
—
Expires
2017-05-03
Drug substance claim
No
Drug product claim
No
Assignee
KAT Transdermals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.